U.S. markets open in 30 minutes

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.0752-0.0029 (-3.71%)
At close: 04:00PM EDT
0.0750 -0.00 (-0.27%)
Pre-Market: 08:46AM EDT

Ampio Pharmaceuticals, Inc.

373 Inverness Parkway
Suite 200
Englewood, CO 80112
United States
720 437 6500

Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael A. MartinoCEO & Director585.71kN/A1957
Dr. David Bar-Or M.D.Founder & Chairman of Scientific Advisory Board38.5kN/A1949
Mr. Daniel G. Stokely CPA, CPACFO, Corp. Sec. & Treasurer301.36kN/A1964
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.Chief Medical OfficerN/AN/A1954
Lane HapkeVP of Manufacturing OperationsN/AN/AN/A
April RamirezClinical Trial Mang.N/AN/AN/A
Laura GoldbergVP of Quality and Regulatory OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Corporate Governance

Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.